- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of April 1
The Center for Biosimilars® recaps the top news for the week of April 1, 2019.
Transcript
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 1.
Number 5: A new consensus report calls the nocebo effect underrecognized in the area of biosimilars and says that more research is needed on this important topic.
Number 4: Stakeholders testified before a House of Representatives subcommittee about the impact of the rising costs of insulin.
Number 3: A head-to-head study, published in The Lancet, has produced data that may help allay gastroenterologists’ concerns about using CT-P13 in Corhn disease.
Number 2: Sandoz announced that it has resubmitted its Biologics License Application for its pegfilgrastim biosimilar referencing Neulasta.
Number 1: Yet another class action lawsuit has been filed against AbbVie, maker of Humira. This time, Baltimore, Maryland, is suing both AbbVie and Amgen for delayed biosimilar competition.
Finally, last week, our e-newsletter asked whether you agree with the FDA’s decision to require 4-letter suffixes only for newly approved biologics and biosimlars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Senators Introduce Bipartisan Legislation to Protect Skinny Labeling
January 2nd 2025To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.
